Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study

Aina Y, Susman JL (2006) Understanding comorbidity with depression and anxiety disorders. J Am Osteopath Assoc 106:S9–S14 Bonaventure P, Kelly L, Aluisio L, Shelton J, Lord B, Galici R, Miller K, Atack J, Lovenberg TW, Dugovic C (2007) Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J Pharmacol Exp Ther 321:690–698 Borsini F, Lecci A, Mancinelli A, D’Aranno V, Meli A (1988) Stimulation of dopamine D-2 but not D-1 receptors reduces immobility time of rats in the forced swimming test: implication for antidepressant activity. Eur J Pharmacol 148:301–307 Borsini F, Podhorna J, Marazziti D (2002) Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology (Berl) 163:121–141 Bourin M, Chenu F, Ripoll N, David DJ (2005) A proposal of decision tree to screen putative antidepressants using forced swim and tail suspension tests. Behav Brain Res 164:266–269 Brocco M, Dekeyne A, Papp M, Millan MJ (2006) Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behav Pharmacol 17:559–572 Brodkin J, Busse C, Sukoff SJ, Varney MA (2002) Anxiolytic-like activity of the mGluR5 antagonist MPEP a comparison with diazepam and buspirone. Pharmacol Biochem Behav 73:359–366 Broekkamp CL, Rijk HW, Joly-Gelouin D, Lloyd KL (1986) Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur J Pharmacol 126:223–229 Broekkamp CL, Berendsen HH, Jenck F, Van Delft AM (1989) Animal models for anxiety and response to serotonergic drugs. Psychopathology 22(Suppl 1):2–12 Cartmell J, Perry KW, Salhoff CR, Monn JA, Schoepp DD (2001) Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade. Neuropharmacology 40:847–855 Chouinard G, Annable L, Bradwejn J (1984) An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacology (Berl) 83:126–128 Cooper BR, Hester TJ, Maxwell RA (1980) Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther 215:127–134 Coppen A (1967) The biochemistry of affective disorders. Br J Psychiatry 113:1237–1264 Cryan JF, Dalvi A, Jin SH, Hirsch BR, Lucki I, Thomas SA (2001) Use of dopamine-beta-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs. J Pharmacol Exp Ther 298:651–657 Cryan JF, Mombereau C, Vassout A (2005a) The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29:571–625 Cryan JF, Valentino RJ, Lucki I (2005b) Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 29:547–569 Davidson RJ (2002) Anxiety and affective style: role of prefrontal cortex and amygdala. Biol Psychiatry 51:68–80 Dawson PA, Steane SE, Markovich D (2004) Behavioural abnormalities of the hyposulphataemic Nas1 knock-out mouse. Behav Brain Res 154:457–463 Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, Cox LM, Gibbs JP, Gibbs MA, Hatch H, Hop CE, Kasman IN, Laperle J, Liu J, Liu X, Logman M, Maclin D, Nedza FM, Nelson F, Olson E, Rahematpura S, Raunig D, Rogers S, Schmidt K, Spracklin DK, Szewc M, Troutman M, Tseng E, Tu M, Van Deusen JW, Venkatakrishnan K, Walens G, Wang EQ, Wong D, Yasgar AS, Zhang C (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33:165–174 Fontaine R, Chouinard G (1986) An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 6:98–101 Franklin KBJ, Paxinos GT (1997) The mouse brain in stereotaxic coordinates. Academic, New York Frazer A, Morilak DA (2005) What should animal models of depression model? Neurosci Biobehav Rev 29:515–523 Gartside SE, McQuade R, Sharp T (1997) Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on 5-HT cell firing and release: comparison between dorsal and median raphe 5-HT systems. Neuropharmacology 36:1697–1703 Gillman PK (2007) Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 151:737–748 Gingrich JA (2002) Mutational analysis of the serotonergic system: recent findings using knockout mice. Curr Drug Targets CNS Neurol Disord 1:449–465 Grimsley SR, Jann MW (1992) Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 11:930–957 Gyertyan I (1995) Analysis of the marble burying response: marbles serve to measure digging rather than evoke burying. Behav Pharmacol 6:24–31 Hirano K, Kato Y, Uchida S, Sugimoto Y, Yamada J, Umegaki K, Yamada S (2004) Effects of oral administration of extracts of Hypericum perforatum (St John’s wort) on brain serotonin transporter, serotonin uptake and behaviour in mice. J Pharm Pharmacol 56:1589–1595 Hirano K, Kimura R, Sugimoto Y, Yamada J, Uchida S, Kato Y, Hashimoto H, Yamada S (2005) Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Br J Pharmacol 144:695–702 Hyttel J (1993) Comparative pharmacology of selective serotonin reuptake inhibitors (SSRIs). Nord J Psychiatry 47(suppl 30):5–12 Ichimaru Y, Egawa T, Sawa A (1995) 5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Jpn J Pharmacol 68:65–70 Inagaki N, Igeta K, Kim JF, Nagao M, Shiraishi N, Nakamura N, Nagai H (2002) Involvement of unique mechanisms in the induction of scratching behavior in BALB/c mice by compound 48/80. Eur J Pharmacol 448:175–183 Kitada Y, Miyauchi T, Satoh A, Satoh S (1981) Effects of antidepressants in the rat forced swimming test. Eur J Pharmacol 72:145–152 Lee JJ, Croucher MJ (2003) Actions of Group I and Group II metabotropic glutamate receptor ligands on 5-hydroxytryptamine release in the rat cerebral cortex in vivo: differential roles in the regulation of central serotonergic neurotransmission. Neuroscience 117:671–679 Li SX, Perry KW, Wong DT (2002) Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 42:181–190 Li X, Morrow D, Witkin JM (2006) Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying. Life Sci 78:1933–1939 Londei T, Valentini AM, Leone VG (1998) Investigative burying by laboratory mice may involve non-functional, compulsive, behaviour. Behav Brain Res 94:249–254 Lucki I, Dalvi A, Mayorga AJ (2001) Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl) 155:315–322 Maas JW, Huang Y (1980) Noradrenergic function and depression, too much or too little? Can J Neurol Sci 7:267–268 Mann JJ (1999) Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 21:99S–105S Matsushita M, Egashira N, Harada S, Okuno R, Mishima K, Iwasaki K, Nishimura R, Fujiwara M (2005) Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder. J Pharmacol Sci 99:154–159 Millan MJ, Dekeyne A, Papp M, La Rochelle CD, MacSweeny C, Peglion JL, Brocco M (2001a) S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 298:581–591 Millan MJ, Gobert A, Lejeune F, Newman-Tancredi A, Rivet JM, Auclair A, Peglion JL (2001b) S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 298:565–580 Millan MJ, Girardon S, Mullot J, Brocco M, Dekeyne A (2002) Stereospecific blockade of marble-burying behaviour in mice by selective, non-peptidergic neurokinin1 (NK1) receptor antagonists. Neuropharmacology 42:677–684 Millan MJ, Brocco M, Papp M, Serres F, La Rochelle CD, Sharp T, Peglion JL, Dekeyne A (2004) S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole. J Pharmacol Exp Ther 309:936–950 Montgomery SA (1997) Is there a role for a pure noradrenergic drug in the treatment of depression? Eur Neuropsychopharmacol 7(Suppl 1):S3–S9; discussion S71–3 Nelson JC (1999) A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry 46:1301–1308 Ninan PT (2003) Obsessive-compulsive disorder: implications of the efficacy of an SSRI, paroxetine. Psychopharmacol Bull 37(Suppl 1):89–96 Njung’e K, Handley SL (1991a) Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents. Br J Pharmacol 104:105–112 Njung’e K, Handley SL (1991b) Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 38:63–67 Nutt D (2000) Treatment of depression and concomitant anxiety. Eur Neuropsychopharmacol 10(Suppl 4):S433–S437 Pacher P, Kecskemeti V (2004) Trends in the development of new antidepressants. Is there a light at the end of the tunnel? Curr Med Chem 11:925–943 Poling A, Cleary J, Monaghan M (1981) Burying by rats in response to aversive and nonaversive stimuli. J Exp Anal Behav 35:31–44 Porsolt RD (1979) Animal model of depression. Biomedicine 30:139–140 Porsolt RD (1990) Behavioral despair: present status and future perspectives. CNS Publishers, London Porsolt RD, Lenegre A (1992) Behavioral models of depression. Wiley, London Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327–336 Porsolt RD, Bertin A, Blavet N, Deniel M, Jalfre M (1979) Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity. Eur J Pharmacol 57:201–210 Porsolt RD, Lenegre A, McArthur RA (1991) Pharmacological models of depression. Birkhäuser Verlag, Basel Price LH, Goodman WK, Charney DS, Rasmussen SA, Heninger GR (1987) Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychiatry 144:1059–1061 Rapoport JL (1988) The neurobiology of obsessive-compulsive disorder. JAMA 260:2888–2890 Reith ME, Li MY, Yan QS (1997) Extracellular dopamine, norepinephrine, and serotonin in the ventral tegmental area and nucleus accumbens of freely moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers. Psychopharmacology (Berl) 134:309–317 Rickels K, Schweizer E (1990) Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 51(Suppl B):9–12 Sanchez C, Hyttel J (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19:467–489 Sandler M (1992) Development of anxiolytic and antidepressant drugs: a historical perspective. Wiley, New York Schechter MD, Chance WT (1979) Non-specificity of “behavioral despair” as an animal model of depression. Eur J Pharmacol 60:139–142 Sharp T, Bramwell SR, Clark D, Grahame-Smith DG (1989) In vivo measurement of extracellular 5-hydroxytryptamine in hippocampus of the anaesthetized rat using microdialysis: changes in relation to 5-hydroxytryptaminergic neuronal activity. J Neurochem 53:234–240 Shimamura M, Kuratani K, Kinoshita M (2007) A new automated and high-throughput system for analysis of the forced swim test in mice based on magnetic field changes. J Pharmacol Toxicol Methods 55:332–336 Shinomiya K, Fujii Y, Sugimoto Y, Azuma N, Tokunaga S, Kitazumi K, Kamei C (2005) Effect of paroxetine on marble-burying behavior in mice. Methods Find Exp Clin Pharmacol 27:685–687 Sprouse JS, Bradberry CW, Roth RH, Aghajanian GK (1989) MDMA (3,4-methylenedioxymethamphetamine) inhibits the firing of dorsal raphe neurons in brain slices via release of serotonin. Eur J Pharmacol 167:375–383 Sprouse JS, Bradberry CW, Roth RH, Aghajanian GK (1990) 3,4-Methylenedioxymethamphetamine-induced release of serotonin and inhibition of dorsal raphe cell firing: potentiation by l-tryptophan. Eur J Pharmacol 178:313–320 Takeuchi H, Yatsugi S, Yamaguchi T (2002) Effect of YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT 2A receptor antagonistic activity, on a marble-burying behavior test as an obsessive-compulsive disorder model. Jpn J Pharmacol 90:197–200 Tauscher J, Bagby RM, Javanmard M, Christensen BK, Kasper S, Kapur S (2001) Inverse relationship between serotonin 5-HT(1A) receptor binding and anxiety: a [(11)C]WAY-100635 PET investigation in healthy volunteers. Am J Psychiatry 158:1326–1328 Treit D, Pinel JP, Fibiger HC (1981) Conditioned defensive burying: a new paradigm for the study of anxiolytic agents. Pharmacol Biochem Behav 15:619–626 Van der Meersch-Mougeot V, da Rocha M Jr, Monier C, Diquet B, Puech AJ, Thiebot MH (1993) Benzodiazepines reverse the anti-immobility effect of antidepressants in the forced swimming test in mice. Neuropharmacology 32:439–446 Velasco F, Velasco M, Jimenez F, Velasco AL, Salin-Pascual R (2005) Neurobiological background for performing surgical intervention in the inferior thalamic peduncle for treatment of major depression disorders. Neurosurgery 57:439–448; discussion 439–48 Waldmeier PC (1981) Noradrenergic transmission in depression: under- or overfunction? Pharmacopsychiatria 14:3–9 Wilkie DM, MacLennan AJ, Pinel JP (1979) Rat defensive behavior: burying noxious food. J Exp Anal Behav 31:299–306 Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP, Hyslop DK, Franklin S, Porsolt RD, Bonsignori A, Carfagna N, McArthur RA (2000) Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 47:818–829 Yazici O, Aricioglu F, Gurvit G, Ucok A, Tastaban Y, Canberk O, Ozguroglu M, Durat T, Sahin D (1993) Noradrenergic and serotoninergic depression? J Affect Disord 27:123–129